Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Neuropsychopharmacology. 2011 Feb 16;36(6):1260–1274. doi: 10.1038/npp.2011.12

Figure 2.

Figure 2

Acute administration of LY379268 reverses the NMDA receptor expression induced by MK-801 treatment. (A) Representative western blot showing the expressions of NR1, NR2B, and pNR2BTyr1472 under different treatment groups. (B) Summary histogram showing the comparisons of altered NR2A, NR2B, and pNR2BTyr1472. Single low-dose MK-801 (0.033mg/kg, acute, i.p) induced a significant increase of NR2B (P <0.05) and a decrease of pNR2BTyr1472 (P <0.05), but had effect on NR2A (P >0.05). Acute LY379268 (0.3 mg/kg) treatment at low dose, either prior to or after MK-801 administration, partially reversed the MK-801 effects on NR2B and pNR2BTyr1472 expressions. In contrast, high-dose MK-801 (1 mg/kg) significantly decreased both NR2A and NR2B, as well as pNR2BTyr1472 expression (P <0.05). LY379268 (3 mg/kg), when applied 50 min after, but not 30 min prior to, MK-801 administration, partially reversed NR2A but not NR2B, and completely recovered pNR2BTyr1472 to control level.